Obsessive-compulsive symptom dimensions correlate to specific gray matter volumes in treatment-naive patients
Carregando...
Citações na Scopus
51
Tipo de produção
article
Data de publicação
2012
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
ROSARIO, Maria C. do
DOUGHERTY, Darin D.
BRESSAN, Rodrigo A.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF PSYCHIATRIC RESEARCH, v.46, n.12, p.1635-1642, 2012
Resumo
Background: Clinical and sociodemographic findings have supported that OCD is heterogeneous and composed of multiple potentially overlapping and stable symptom dimensions. Previous neuroimaging investigations have correlated different patterns of OCD dimension scores and gray matter (GM) volumes. Despite their relevant contribution, some methodological limitations, such as patient's previous medication intake, may have contributed to inconsistent findings. Method: Voxel-based morphometry was used to investigate correlations between regional GM volumes and symptom dimensions severity scores in a sample of 38 treatment-naive OCD patients. Several standardized instruments were applied, including an interview exclusively developed for assessing symptom dimensions severity (DY-BOCS). Results: Scores on the ""aggression"" dimension were positively correlated with GM volumes in lateral parietal cortex in both hemispheres and negatively correlated with bilateral insula, left putamen and left inferior OFC. Scores on the ""sexual/religious"" dimension were positively correlated with GM volumes within the right middle lateral OFC and right DLPFC and negatively correlated with bilateral ACC. Scores on the ""hoarding"" dimension were positively correlated with GM volumes in the left superior lateral OFC and negatively correlated in the right parahippocampal gyrus. No significant correlations between GM volumes and the ""contamination"" or ""symmetry"" dimensions were found. Conclusions: Building upon preexisting findings, our data with treatment-naive OCD patients have demonstrated distinct GM substrates implicated in both cognitive and emotion processing across different OCS dimensions.
Palavras-chave
Obsessive-compulsive disorder (OCD), Symptom dimensions, Neuroimaging, Voxel-based morphometry (VBM), Treatment-naive, Gray matter (GM)
Referências
- ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L
- Anholt GE, 2009, J ANXIETY DISORD, V23, P830, DOI 10.1016/j.janxdis.2009.04.004
- Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018
- BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
- Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756
- Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585
- Chamberlain SR, 2005, NEUROSCI BIOBEHAV R, V29, P399, DOI 10.1016/j.neubiorev.2004.11.006
- Cuadra MB, 2005, IEEE T MED IMAGING, V24, P1548, DOI 10.1109/TMI.2005.857652
- Delucchi KL, 2004, AM J PSYCHIAT, V161, P1159, DOI 10.1176/appi.ajp.161.7.1159
- First M.B., 1997, STRUCTURED CLIN INTE
- Friston K., 1995, HUM BRAIN MAPP, V2, P189
- Fullana MA, 2009, AM J PSYCHIAT, V166, P329, DOI [10.1176/appi.ajp.2008.08071006, 10.1176/appi.ajp.2008/08071006]
- Gilbert AR, 2008, J AFFECT DISORDERS, V109, P117, DOI 10.1016/j.jad.2007.12.223
- Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786
- GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
- Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027
- Grisham JR, 2009, BRIT J PSYCHIAT, V195, P138, DOI 10.1192/bjp.bp.108.056812
- Hoexter MQ, 2012, NEUROPSYCHOPHARMACOL, V37, P734, DOI 10.1038/npp.2011.250
- Hoexter Marcelo Queiroz, 2009, Rev Bras Psiquiatr, V31, P349
- Huyser C, 2009, NEUROSCI BIOBEHAV R, V33, P818, DOI 10.1016/j.neubiorev.2009.01.003
- Lawrence NS, 2007, BIOL PSYCHIAT, V61, P1072, DOI 10.1016/j.biopsych.2006.06.033
- Leckman JF, 2007, CNS SPECTRUMS, V12, P376
- Mataix-Cols D, 2006, PSYCHIAT CLIN N AM, V29, P391, DOI 10.1016/j.psc.2006.02.006
- Mataix-Cols D, 2003, BIOL PSYCHIAT, V53, P482, DOI 10.1016/S0006-3223(03)01504-4
- Mataix-Cols D, 2011, J CLIN PSYCHOL, V67, P467, DOI 10.1002/jclp.20791
- Mataix-Cols D, 2005, AM J PSYCHIAT, V162, P228, DOI 10.1176/appi.ajp.162.2.228
- Mataix-Cols D, 2004, ARCH GEN PSYCHIAT, V61, P564, DOI 10.1001/archpsyc.61.6.564
- Menzies L, 2008, NEUROSCI BIOBEHAV R, V32, P525, DOI 10.1016/j.neubiorev.2007.09.005
- Moll J, 2009, NEUROSCI BIOBEHAV R, V33, P456, DOI 10.1016/j.neubiorev.2008.12.001
- Morein-Zamir S, 2010, PSYCHOPHARMACOLOGY, V212, P357, DOI 10.1007/s00213-010-1963-z
- Nagai M, 2007, EUR PSYCHIAT, V22, P387, DOI 10.1016/j.eurpsy.2007.02.006
- Nishida S, 2011, PROG NEURO-PSYCHOPH, V35, P997, DOI 10.1016/j.pnpbp.2011.01.022
- Pujol J, 2004, ARCH GEN PSYCHIAT, V61, P720, DOI 10.1001/archpsyc.61.7.720
- Radua J, 2009, BRIT J PSYCHIAT, V195, P393, DOI 10.1192/bjp.bp.108.055046
- Rauch S. L., 1998, CNS SPECTRUMS, V3, P37
- Rosario-Campos MC, 2006, MOL PSYCHIATR, V11, P495, DOI 10.1038/sj.mp.4001798
- Rotge JY, 2009, BIOL PSYCHIAT, V65, P75, DOI 10.1016/j.biopsych.2008.06.019
- Song A, 2011, PLOS ONE, V6
- Szeszko PR, 2005, ARCH GEN PSYCHIAT, V62, P782, DOI 10.1001/archpsyc.62.7.782
- Talairach J, 1988, COPLANAR STEREOTAXIC
- Tolin DF, 2009, PSYCHOL MED, V39, P325, DOI 10.1017/S0033291708003371
- Valente AA, 2005, BIOL PSYCHIAT, V58, P479, DOI 10.1016/j.biopsych.2005.04.021
- van den Heuvel OA, 2009, BRAIN, V132, P853, DOI 10.1093/brain/awn267
- Yucel M, 2007, ARCH GEN PSYCHIAT, V64, P946, DOI 10.1001/archpsyc.64.8.946